Small Interfering RNA-induced TLR3 Activation Inhibits Blood and Lymphatic Vessel Growth

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2009 Apr 11

PMID 19359485

Citations 67

Authors

Won Gil Cho

Romulo J C Albuquerque

Mark E Kleinman

Valeria Tarallo

Adelaide Greco

Miho Nozaki

Martha G Green

Judit Z Baffi

Balamurali K Ambati

Massimo De Falco

Jonathan S Alexander

Arturo Brunetti

Sandro De Falco

Jayakrishna Ambati

Affiliations

Soon will be listed here.

Abstract

Neovascularization in response to tissue injury consists of the dual invasion of blood (hemangiogenesis) and lymphatic (lymphangiogenesis) vessels. We reported recently that 21-nt or longer small interfering RNAs (siRNAs) can suppress hemangiogenesis in mouse models of choroidal neovascularization and dermal wound healing independently of RNA interference by directly activating Toll-like receptor 3 (TLR3), a double-stranded RNA immune receptor, on the cell surface of blood endothelial cells. Here, we show that a 21-nt nontargeted siRNA suppresses both hemangiogenesis and lymphangiogenesis in mouse models of neovascularization induced by corneal sutures or hindlimb ischemia as efficiently as a 21-nt siRNA targeting vascular endothelial growth factor-A. In contrast, a 7-nt nontargeted siRNA, which is too short to activate TLR3, does not block hemangiogenesis or lymphangiogenesis in these models. Exposure to 21-nt siRNA, which we demonstrate is not internalized unless cell-permeating moieties are used, triggers phosphorylation of cell surface TLR3 on lymphatic endothelial cells and induces apoptosis. These findings introduce TLR3 activation as a method of jointly suppressing blood and lymphatic neovascularization and simultaneously raise new concerns about the undesirable effects of siRNAs on both circulatory systems.

Citing Articles

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.

Nemunaitis J, Stanbery L, Walter A, Wallraven G, Nemunaitis A, Horvath S Future Oncol. 2024; 20(29):2149-2164.

PMID: 39101448 PMC: 11509044. DOI: 10.1080/14796694.2024.2376518.

Molecular Therapies in Cardiovascular Diseases: Small Interfering RNA in Atherosclerosis, Heart Failure, and Hypertension.

Sarzani R, Spannella F, Di Pentima C, Giulietti F, Landolfo M, Allevi M Int J Mol Sci. 2024; 25(1).

PMID: 38203499 PMC: 10778861. DOI: 10.3390/ijms25010328.

A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy.

Zhang J, Chen B, Gan C, Sun H, Zhang J, Feng L Int J Nanomedicine. 2023; 18:7605-7635.

PMID: 38106451 PMC: 10725753. DOI: 10.2147/IJN.S436038.

Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy.

Sharma P, Otto M Bioact Mater. 2023; 31:440-462.

PMID: 37701452 PMC: 10494322. DOI: 10.1016/j.bioactmat.2023.08.022.

Toll-like Receptors as Pro-Thrombotic Drivers in Viral Infections: A Narrative Review.

Panzer B, Kopp C, Neumayer C, Koppensteiner R, Jozkowicz A, Poledniczek M Cells. 2023; 12(14).

PMID: 37508529 PMC: 10377790. DOI: 10.3390/cells12141865.

References

Fenwick A . Waterborne infectious diseases--could they be consigned to history?. Science. 2006; 313(5790):1077-81. DOI: 10.1126/science.1127184. View

Yang Z, Stratton C, Francis P, Kleinman M, Tan P, Gibbs D . Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med. 2008; 359(14):1456-63. PMC: 2573951. DOI: 10.1056/NEJMoa0802437. View

Choe J, Kelker M, Wilson I . Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science. 2005; 309(5734):581-5. DOI: 10.1126/science.1115253. View

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M . Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004; 432(7014):173-8. DOI: 10.1038/nature03121. View

Kaiser W, Offermann M . Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J Immunol. 2005; 174(8):4942-52. DOI: 10.4049/jimmunol.174.8.4942. View

Alexopoulou L, Holt A, Medzhitov R, Flavell R . Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001; 413(6857):732-8. DOI: 10.1038/35099560. View

Heidemann J, Ruther C, Kebschull M, Domschke W, Bruwer M, Koch S . Expression of IL-12-related molecules in human intestinal microvascular endothelial cells is regulated by TLR3. Am J Physiol Gastrointest Liver Physiol. 2007; 293(6):G1315-24. DOI: 10.1152/ajpgi.00142.2007. View

Takada E, Okahira S, Sasai M, Funami K, Seya T, Matsumoto M . C-terminal LRRs of human Toll-like receptor 3 control receptor dimerization and signal transmission. Mol Immunol. 2007; 44(15):3633-40. DOI: 10.1016/j.molimm.2007.04.021. View

Wolfrum C, Shi S, Narayanannair Jayaprakash K, Jayaraman M, Wang G, Pandey R . Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007; 25(10):1149-57. DOI: 10.1038/nbt1339. View

10.

Chiu Y, Ali A, Chu C, Cao H, Rana T . Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol. 2004; 11(8):1165-75. DOI: 10.1016/j.chembiol.2004.06.006. View

11.

Ando T, Jordan P, Joh T, Wang Y, Jennings M, Houghton J . Isolation and characterization of a novel mouse lymphatic endothelial cell line: SV-LEC. Lymphat Res Biol. 2005; 3(3):105-15. DOI: 10.1089/lrb.2005.3.105. View

12.

Salaun B, Coste I, Rissoan M, Lebecque S, Renno T . TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006; 176(8):4894-901. DOI: 10.4049/jimmunol.176.8.4894. View

13.

Judge A, Sood V, Shaw J, Fang D, McClintock K, MacLachlan I . Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005; 23(4):457-62. DOI: 10.1038/nbt1081. View

14.

Kleinman M, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi J . Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452(7187):591-7. PMC: 2642938. DOI: 10.1038/nature06765. View

15.

Jackson A, Bartz S, Schelter J, Kobayashi S, Burchard J, Mao M . Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003; 21(6):635-7. DOI: 10.1038/nbt831. View

16.

Lundberg A, Drexler S, Monaco C, Williams L, Sacre S, Feldmann M . Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood. 2007; 110(9):3245-52. DOI: 10.1182/blood-2007-02-072934. View

17.

Han K, Su X, Xu L, Bin L, Zhang J, Shu H . Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways. J Biol Chem. 2004; 279(15):15652-61. DOI: 10.1074/jbc.M311629200. View

18.

Bell J, Botos I, Hall P, Askins J, Shiloach J, Segal D . The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci U S A. 2005; 102(31):10976-80. PMC: 1182468. DOI: 10.1073/pnas.0505077102. View

19.

Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S . Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005; 11(3):263-70. DOI: 10.1038/nm1191. View

20.

Carmeliet P . Angiogenesis in life, disease and medicine. Nature. 2005; 438(7070):932-6. DOI: 10.1038/nature04478. View